Skip to main content
Article thumbnail
Location of Repository

Case Report Successful Intravenous Regional Block with Low-Dose Tumor Necrosis Factor- � Antibody Infliximab for Treatment of Complex Regional Pain Syndrome 1

By Michael Bernateck Md, Roman Rolke Md, Frank Birklein Md, Rolf-detlef Treede Md and Matthias Fink Md


Cytokines, particularly tumor necrosis factor-�, may play an important role in the mediation of mechanical hyperalgesia and autonomic signs in complex regional pain syndrome 1. We performed an IV regional block with low-dose administration of the tumor necrosis factor- � antibody, infliximab, in a patient with typical clinical signs of complex regional pain syndrome 1 (moderate pain, edema, hyperhidrosis, elevated skin temperature compared with the contralateral side). A significant improvement of clinical variables was observed 24 h after infliximab treatment. Almost complete remission was reached within 8 wk, but sensory signs improved only after 6 mo. No adverse events were observed. (Anesth Analg 2007;105:1148–51) Matthias Karst, MD* Chronic complex regional pain syndrome (CRPS) is characterized by spontaneous pain that is often accompanied by somatosensory disturbances such as mechanical allodynia, and thermal or mechanical hyperalgesia

Topics: From the *Department of Anesthesiology, Pain Clinic, Hannover
Year: 2014
OAI identifier: oai:CiteSeerX.psu:
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.